Thank you for visiting a Salix Pharmaceuticals, Inc. (Salix) Web site. Salix respects the privacy of visitors to our
site (the "Site") and is committed to maintaining your privacy when you visit. We will only collect your personally
identifiable information when you voluntarily provide it to us. From time to time, we may refer to this information to better
understand your needs and how we can improve our services. We may use this information to contact you; however we will not
sell the personally identifiable information you provide to us at this Web site to any third parties for their own use.
As many other companies do, Salix also measures the performance of its site in order to improve and customize it in favor of
our visitors. This Web site may use a technology called "cookies". Generally, a cookie assigns a unique number to the visitor
which has no meaning outside the assigning site. The purpose of this technology and the information it provides is to help us
improve our site. Most Web browsers allow the user to deny or accept the cookie feature. Please note that cookies may be
necessary to provide you with certain features available on this site. In all cases in which cookies are used, neither Salix
nor any third party will use the cookie to collect personally identifiable information unless you voluntarily agree to enter
This site may also maintain Web server logs that can automatically identify your computer by its IP address and collect that
information. An IP address is a number that is automatically assigned to your computer by your Internet service provider.
Salixs Web server logs may collect statistical data that is generated by your computer when it visits the site, such as the
type of Web browser used to access the site and the pages you visit. No personally identifiable information would be contained
in these Web server logs.
Some services on our site may require registration. When you register, you may need to complete certain fields, as well as
choose a user name and password. In these situations, if you choose to withhold any personally identifiable information requested
by us, it may not be possible for you to gain access to certain parts of the site and for us to respond to your query.
for information on their privacy policies.
Salix reserves its right to amend this policy at any time.
Product information contained on this site is intended for US consumers only. OsmoPrep is a registered trademark of Salix
Pharmaceuticals, Inc. Information contained on this website is for informational purposes only and should not replace talking
to your healthcare provider for information related to your health.
Important Safety Information about OsmoPrep
There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior
to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some
cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with
increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using
medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers
[ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).
It is important to use the dose and dosing regimen as recommended (PM/AM split dose).
Please see full Prescribing Information for OsmoPrep, including BOXED WARNING.
OsmoPrep® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing
of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep is used in
patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation,
bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal
function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte
disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as
hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep.
OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with
biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were
abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before,
during, and after the use of OsmoPrep.